Abstract

BackgroundIn vitro drug susceptibility testing of malaria parasites remains an important component of surveillance for anti-malarial drug resistance. The half-maximal inhibition of growth (IC50) is the most commonly reported parameter expressing drug susceptibility, derived by a variety of statistical approaches, each with its own advantages and disadvantages.MethodsIn this study, licensed computer programs WinNonlin and GraphPad Prism 6.0, and the open access programs HN-NonLin, Antimalarial ICEstimator (ICE), and In Vitro Analysis and Reporting Tool (IVART) were tested for their ease of use and ability to estimate reliable IC50 values from raw drug response data from 31 Plasmodium falciparum and 29 P. vivax clinical isolates tested with five anti-malarial agents: chloroquine, amodiaquine, piperaquine, mefloquine, and artesunate.ResultsThe IC50 and slope estimates were similar across all statistical packages for all drugs tested in both species. There was good correlation of results derived from alternative statistical programs and non-linear mixed-effects modelling (NONMEM) which models all isolate data simultaneously. The user-friendliness varied between packages. While HN-NonLin and IVART allow users to enter the data in 96-well format, IVART and GraphPad Prism 6.0 are capable to analyse multiple isolates and drugs in parallel. WinNonlin, GraphPad Prism 6.0, IVART, and ICE provide alerts for non-fitting data and incorrect data entry, facilitating data interpretation. Data analysis using WinNonlin or ICE took the longest computationally, whilst the offline ability of GraphPad Prism 6.0 to analyse multiple isolates and drugs simultaneously made it the fastest among the programs tested.ConclusionIC50 estimates obtained from the programs tested were comparable. In view of processing time and ease of analysis, GraphPad Prism 6.0 or IVART are best suited for routine and large-scale drug susceptibility testing.Electronic supplementary materialThe online version of this article (doi:10.1186/s12936-016-1173-1) contains supplementary material, which is available to authorized users.

Highlights

  • In vitro drug susceptibility testing of malaria parasites remains an important component of surveillance for anti-malarial drug resistance

  • Artemisinin-based combination therapy (ACT) has been implemented widely for the treatment of falciparum malaria and has proven to be Wirjanata et al Malar J (2016) 15:137 beneficial, it is important to consider that resistance to one component of the therapy can be masked by a partner drug which retains high anti-malarial efficacy

  • The population geometric mean half-maximal inhibition of growth (IC50) were similar for the five different methodologies with no significant differences when compared to the non-linear mixed-effects modelling (NONMEM) reference estimates

Read more

Summary

Introduction

In vitro drug susceptibility testing of malaria parasites remains an important component of surveillance for anti-malarial drug resistance. The parasites’ drug susceptibility is defined by measuring growth (i.e., schizont maturation) or replication (i.e., re-invasion assays) in the presence of varying concentrations of antimalarial compounds. These assays are highly informative, the comparison of data between laboratories or field sites is often problematic as numerous variations exist between protocols, such as the initial parasitaemia, incubation time, culture haematocrit, and the use of alternative media and supplements [5, 6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call